

## ERS International Congress 2023 Rare Disease Patient Track

Saturday 9 September							
Time CEST	Session title	Summary	Session type	Patient role	Disease area	Link	Live streamed?
11:15-12:45	Conditions we are just dealing with the tip of the iceberg in primary care	To discuss possible actions to improve management of frequently forbidden conditions in primary health care; to provide general practitioners and primary care professionals with easy tools and strategies to diagnose and manage sleep apnoea, chronic cough and interstitial lung diseases; to reduce the burden of antibiotic resistance.	Primary care session		ILD	<a href="https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=15930">https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=15930</a>	Yes
11:15-12:45	French programme 2023	This session will be delivered in French and translated into English. It will include: <ul style="list-style-type: none"> <li>the plans and commitments of the SPLF's (French Language Pulmonology Society) Strategic Orientation and Commitment Committee to improve lung care</li> <li>the latest recommendations from the ERS and the European Society of Cardiology in 2022 for diagnosing pulmonary hypertension</li> <li>how doctors work together to diagnose and treat pulmonary embolism during pregnancy, ensuring the best care for both the mother and the baby</li> <li>how pulmonary embolism is managed, including where patients receive their treatment and support</li> <li>the conceptual framework of One Health and the Exposome and how it relates to lung health</li> <li>pollution and lung cancer.</li> </ul>	Language session		Pulmonary hypertension	<a href="https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=15927">https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=15927</a>	Yes
13:15-14:45	Italian programme 2023	This session, delivered in Italian with translation, will look at new treatments for chronic obstructive pulmonary diseases (COPD) and fibrotic lung diseases such as IPF. It will also discuss environmental	Language session		Pulmonary fibrosis	<a href="https://k4.ersnet.org/prod/v2/Front/P">https://k4.ersnet.org/prod/v2/Front/P</a>	Yes

## ERS International Congress 2023 Rare Disease Patient Track

		and job-related risk factors, and the use of disposable devices in treatment. It will cover: <ul style="list-style-type: none"> <li>• factors from the environment and employment that can increase the chances of getting fibrotic lung diseases</li> <li>• the latest therapies that have been developed to treat fibrotic lung diseases</li> <li>• new treatments for chronic obstructive lung diseases</li> <li>• disposable devices used in a medical procedure called interventional pulmonology. The session will look at how these single-use devices are helpful in medical procedures, but also consider their impact on the environment.</li> </ul>				<a href="#">rogram/Session?e=379&amp;session=15926</a>	
15:15-16:45	Spanish/Portuguese programme 2023	This session, delivered in Spanish and Portuguese with translation, will explore how biological therapies can be helpful in treating major respiratory diseases that are not caused by infections. It will cover: <ul style="list-style-type: none"> <li>• how biological therapy can benefit people with severe asthma</li> <li>• the latest developments in treatments for lung cancer</li> <li>• how biological treatments can be used to improve the management of COPD</li> <li>• how biological treatments are being used to treat interstitial lung diseases.</li> </ul>	Language session		ILD	<a href="https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=15925">https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=15925</a>	Yes

Sunday 10 September							
Time CEST	Session title	Summary	Session type	Patient role	Disease area	Link	Live streamed?
8:30-10:00	Progressive pulmonary fibrosis:	To describe the magnitude of the problem of progressive pulmonary fibrosis (PPF); to discuss the diagnostic tools to detect or predict PPF; to explore some of the putative pathogenic mechanisms that	Symposium	Includes a patient	Progressive pulmonary fibrosis	<a href="https://k4.ersnet.org/prod/v2/Fr">https://k4.ersnet.org/prod/v2/Fr</a>	Yes

## ERS International Congress 2023 Rare Disease Patient Track

	challenges and controversies	may be involved in the progression of fibrotic lung disorder; to discuss the therapeutic approach, covering immunosuppression and antifibrotic drugs, antifibrotic drugs alone, nonpharmacological support, and when to start and stop this all.		perspective		<a href="https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=15282">ont/Program/Session?e=379&amp;session=15282</a>	
8:30-10:00	Evolving concepts in the management of nonsmall cell lung cancer	To highlight the latest trends in lung cancer and pleural mesothelioma care. Adoption of emerging therapies such as immunotherapy in early-stage nonsmall cell lung cancer (NSCLC) represents a paradigm shift relative to the previous treatment algorithms. Individualised approaches in thoracic surgery and oligometastatic NSCLC are just finding their way into routine care. Likewise, malignant pleural effusion treatment and research of pleural mesothelioma are currently being redefined.	Symposium		Mesothelioma	<a href="https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=15281">https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=15281</a>	Yes
10:15-11:45	Cystic fibrosis in the era of highly effective cystic fibrosis transmembrane conductance regulator modulator therapy	In this session, experts in the field of cystic fibrosis will come together to talk about the latest developments in treating the condition using a highly effective therapy called cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy. It will look at: <ul style="list-style-type: none"> <li>• how CFTR modulator therapy is transforming the way cystic fibrosis is treated</li> <li>• addressing the needs of people with cystic fibrosis now that effective CFTR modulator therapy is available</li> <li>• exploring the future of cystic fibrosis treatment, including new approaches to understand and tackle the condition</li> <li>• discussing how clinical trials play a crucial role in advancing cystic fibrosis treatment and what the future holds in this regard.</li> </ul>	Journal session		Cystic fibrosis	<a href="https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=15924">https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=15924</a>	Yes
10:15-11:45	Disease modification in pulmonary arterial hypertension	To describe the goal for new disease-modifying treatment of pulmonary arterial hypertension (PAH); to review whether the currently available treatments really change PAH evolution; to	Hot topics		Pulmonary arterial hypertension	<a href="https://k4.ersnet.org/prod/v2/Front/Program">https://k4.ersnet.org/prod/v2/Front/Program</a>	Yes

## ERS International Congress 2023 Rare Disease Patient Track

		describe new therapies affecting different signalling pathways that may modify disease progression.				<a href="https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=16323">m/Session?e=379&amp;session=16323</a>	
10:15-11:45	Infectious and noninfectious complications of immunosuppressed patients	To highlight the different complications of immunosuppressed patients; to focus on difficult-to-manage respiratory infections and innovative approaches such as phage therapy and its application, and preventive and treatment strategies for fungal pulmonary infections; to address the pathogenesis and treatment approaches of noninfectious complications, either immune-driven (chronic lung allograft dysfunction (CLAD) and graft-versus-host disease (GVHD)) or drug-related.	Symposium	Includes a patient perspective	Chronic lung allograft dysfunction (CLAD)	<a href="https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=15228">https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=15228</a>	Yes
11:45-13:20	Paediatric year in review	To provide an update on four topics in paediatric respiratory medicine, namely, paediatric asthma in low-income settings, imaging in paediatric respiratory diseases, primary ciliary dyskinesia and long-term consequences of preterm birth; to highlight the most recent and significant literature and developments relating to these topics.	Year in review		Primary ciliary dyskinesia (PCD)	<a href="https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=15943">https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=15943</a>	Yes
13:45-15:15	Better outcomes for adults with chronic breathlessness: earlier diagnosis and management	To review healthcare pathways for people living with chronic breathlessness, from their first presentation to palliation, highlighting the role of integrated care throughout; to critically appraise research and clinical care evaluations of integrated diagnostic pathways for chronic breathlessness to achieve earlier diagnosis and treatment; to discuss the role of artificial intelligence in diagnostic pathways for chronic breathlessness; to review the role of nonpharmacological management for chronic breathlessness including the multidisciplinary team and rehabilitation; to discuss specific causes of breathlessness, such as breathing pattern disorder, exercise-induced laryngeal obstruction and excessive dynamic airway collapse, and their respective management for clinicians to appropriately diagnose and manage breathlessness; to describe	Symposium	Includes a patient perspective	ILD	<a href="https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=15221">https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=15221</a>	Yes

## ERS International Congress 2023 Rare Disease Patient Track

		complex interventions for distressing breathlessness including breathlessness support services.					
13:45-15:15	Pulmonary vascular diseases: Chronic thromboembolic pulmonary hypertension: treating local complications of systemic disease?	To place recent insights into the molecular pathogenesis of chronic thromboembolic pulmonary hypertension (CTEPH) into the context of the existing state of the art knowledge of CTEPH and its implementation in current clinical guidelines; to answer the question is whether and how these insights into pathophysiology will change future treatment of CTEPH and determine prognosis and outcomes for patients; to discuss novel targets for treatment and improvements in pharmacological therapy	State of the art session		Chronic thromboembolic pulmonary hypertension (CTEPH)	<a href="https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=15940">https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=15940</a>	Yes
15:30-17:00	An ageing lung: respiratory disease in the elderly	To explain the cellular, structural and functional changes that take place in the ageing lung; to evaluate the physiological and immunological changes in elderly patients with chronic obstructive pulmonary disease and interstitial lung disease compared with their healthy age-matched counterparts; to familiarise participants with the diagnostic approach as well as the available therapeutic interventions to combat the consequences of the ageing lung; to explain chronic respiratory diseases across the life course and their associations with frailty.	Symposium		ILD	<a href="https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=15237">https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=15237</a>	Yes

Monday 11 September							
Time CEST	Session title	Summary	Session type	Patient role	Disease area	Link	Live streamed?
8:30-10:00	Pulmonary hypertension and interstitial lung diseases: dilemmas in diagnosis and the conundrum of treatment	To provide the latest updates on pulmonary hypertension (PH) due to interstitial lung disease (ILD), including screening/diagnosis, treatment and future research directions. PH often complicates many forms of advanced lung disease, including pulmonary fibrosis; to discuss the main novel achievements (pathophysiology, diagnosis and management) in the field of PH when patients have CLDs; to	Symposium		Pulmonary hypertension	<a href="https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=15875">https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=15875</a>	Yes

## ERS International Congress 2023 Rare Disease Patient Track

		strengthen understanding of PH due to lung diseases and to improve the care and quality of life of affected patients.					
8:30-10:00	Exercise training, physical activity and self-management at home	To identify the core components, efficacy, strengths, limitations, evidence gaps and research necessary to guide the future delivery of home-based care and pulmonary rehabilitation; to describe patient and outcome assessment, exercise training, physical activity and self-management at home.	Mini symposium		ILD	<a href="https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=15948">https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=15948</a>	Yes
08:30-10:00	Clinical challenges beyond guidelines	<p>This session will discuss some controversial issues related to certain guidelines in healthcare. It will:</p> <ul style="list-style-type: none"> <li>• look at why some aspects of these guidelines are controversial and might be disagreed upon by healthcare professionals</li> <li>• outline data that supports the idea of not always following the current recommendations and consider alternative approaches</li> <li>• propose evidence-based alternative management recommendations for doctors and specialists to consider</li> <li>• highlight areas of concern in these guidelines and where improvements might be needed</li> <li>• emphasise the importance of further research in these areas to better understand and address the controversies and uncertainties.</li> </ul> <p>Specifically, it will cover:</p> <ul style="list-style-type: none"> <li>• adult bronchiectasis</li> <li>• environmental health prevention and air pollution standards</li> <li>• Langerhans' cell histiocytosis in adults</li> <li>• Stage I non-small cell lung cancer.</li> </ul>	Clinical cases		Bronchiectasis / Langerhans' cell histiocytosis	<a href="https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=15954">https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=15954</a>	Yes

## ERS International Congress 2023 Rare Disease Patient Track

10:15-11:45	Emerging evidence to improve quality of survival after critical illness: How can we best manage the rehabilitation needs of intensive care unit survivors?	To address issues pertaining to the optimal frequency, modality and timing of early rehabilitation in critically ill patients based on the results of a recent landmark multicentre trial; to discuss the role of respiratory muscle conditioning in improving weaning outcomes and functional recovery of mechanically ventilated patients based on the results of the recent IMPROVE randomised trial; to increase awareness of the complicated and persistent morbidity and resulting rehabilitation needs that follow critical illness, reviewing recent studies on outcomes after critical illness; to provide experts with guidance on how to design a personalised rehabilitation program for intensive care unit survivors.	Hot Topics	Includes a patient perspective	ILD	<a href="https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=16311">https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=16311</a>	Yes
10:15-11:45	Difficult treatment decisions in pulmonary hypertension	To discuss different treatment possibilities for pulmonary hypertension (PH) patients with right heart failure, including the use of catecholamines, the impact of mechanical ventilation and the use of extracorporeal membrane oxygenation; to describe the risks of pregnancy in patients with pulmonary arterial hypertension (PAH), including the risks in delivery and the postpartum period; to discuss different clinical approaches to pregnancy in PAH patients; to discuss the difficulties in treating elderly PAH patients with multiple comorbidities; to highlight care of end-stage PAH patients and options for palliative care.	Symposium		Pulmonary hypertension / Pulmonary arterial hypertension	<a href="https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=15230">https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=15230</a>	Yes
13:45-14:00	Thoracic oncology	To present four selected hot topics that are currently in the scientific spotlight of thoracic oncology care; –to explain how pulmonologists can within their expertise treat and guide patients throughout the entire continuum of thoracic malignancies in close collaboration with other relevant disciplines and professions.	State of the art session		Mesothelioma	<a href="https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=15938">https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=15938</a>	Yes
13:45-15:15	The role of novel imaging modalities in sarcoidosis	To discuss pivotal role of imaging in diagnosis and follow-up of patients with sarcoidosis; to point out the most appropriate imaging studies, stressing their advantages in various forms of sarcoidosis; to	Hot topics		Sarcoidosis	<a href="https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=15938">https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=15938</a>	Yes

## ERS International Congress 2023 Rare Disease Patient Track

	diagnosis and management	emphasise the important role of high-resolution computed tomography (HRCT) for detection and assessment of subtle parenchymal lesions and abnormalities of lung structures; to present role of HRCT and newly emerging photon counting CT (PCCT) in differentiating active inflammation from irreversible lung disease and fibrosis; to discuss use of magnetic resonance imaging (MRI) for evaluating the involvement of the myocardium in sarcoidosis, as well as increased interest in the role of diffusion-weighted MRI for the characterisation of mediastinal lymphadenopathy.				<a href="https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=16324">ont/Program/Session?e=379&amp;session=16324</a>	
15:30-17:00	Digital solutions for respiratory medicine: a new way of working	To review how adoption of an electronic health records system has created opportunities for respiratory patients to receive better care; to evaluate digital health services for respiratory patients; to discuss the role of big data analytics in respiratory care; to assess artificial intelligence (AI) solutions for imaging, pathology, spirometry, real-time assistance, etc; to discuss the potential drawbacks and advances of using digital technologies during the war in Ukraine.	Hot topics		ILD	<a href="https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=16312">https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=16312</a>	Yes
15:30-17:00	Post-viral lung diseases: from basic immunology to clinical phenotypes and therapy	To present the very best of international lung science research; to highlight new discoveries that will likely impact the future of respiratory medicine; to encourage debate and interaction between basic scientists and clinical researchers on the topic of how respiratory infections cause long-term consequences that give rise to chronic lung diseases such as asthma and pulmonary fibrosis.	Symposium		ILD / Pulmonary fibrosis	<a href="https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=16336">https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=16336</a>	Yes
15:30-17:00	Precision medicine in airways disease: where is the science going and what can we offer in the clinic?	To update European Respiratory Society members on the role of precision medicine in airway diseases.	Hot topics		Bronchiectasis	<a href="https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=16317">https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=16317</a>	Yes



## ERS International Congress 2023 Rare Disease Patient Track

Tuesday 12 September							
Time CEST	Session title	Summary	Session type	Patient role	Disease area	Link	Live streamed?
8:30-10:00	The organ-wide reach of exercise in chronic respiratory disease - a holistic approach	To explain the role of inter-organ crosstalk and cellular communication in relation to exercise; to describe the beneficial effects of exercise training on skeletal muscle; to explain how to identify persons with chronic respiratory disease (CRD) that need additional support during exercise training to have optimal organ-wide effects; to allow participants to engage in discussion on the controversial idea that exercise can regenerate the lung.	Symposium	Includes a patient perspective	ILD	<a href="https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=16321">https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=16321</a>	Yes
10:15-11:45	Pulmonary hypertension related to heart and lung disease	To define the different physiological and clinical characteristics of pulmonary hypertension (PH) associated with different forms of heart or lung diseases; to explain the up-to-date treatment approach for PH associated with heart or lung disease; to explain the different physiological responses of the right ventricle in different types of PH and its impact on the correct treatment and its efficacy; to describe the up-to-date treatment of PH associated with heart failure, with an emphasis on HFpEF-PH.	Respiratory medicine meets other disciplines		Pulmonary hypertension	<a href="https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=15368">https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=15368</a>	Yes
10:15-11:45	Symptom burden in interstitial lung disease	To provide the audience with updates on the pathogenesis, epidemiology and pharmacological and nonpharmacological management of dyspnoea, cough and fatigue in ILD; to learn about the impact of these symptoms on general and emotional well-being and daily activities of the patient; to provide an overview of the most common and burdensome symptoms in patients with ILD; to update on the most recent scientific evidence with regards to the pathophysiology and management of dyspnoea, cough and fatigue, and their impact on patients.	Mini symposium	Includes a patient perspective	ILD	<a href="https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=15949">https://k4.ersnet.org/prod/v2/Front/Program/Session?e=379&amp;session=15949</a>	Yes

## ERS International Congress 2023 Rare Disease Patient Track

13:45-15:15	Interstitial lung diseases: filling the gaps in care for interstitial lung diseases	To discuss: 1) the primary care setting, exploring symptom evaluation in ILDs; 2) the novel assessment of idiopathic pulmonary fibrosis (IPF) management in light of different phase 3 clinical trials of this disease; 3) hypersensitivity pneumonitis (HP) and recent guidelines from different societies, such as novel therapeutic advances after the introduction of antifibrotic therapy in progressive HP; 4) the lungs with the common disease (also in the primary care setting) rheumatoid arthritis, focusing on the ILD component, and, more specifically, address whether its pathogenesis starts from the lungs.	State of the art session		ILD / Idiopathic pulmonary fibrosis (IPF) / Rheumatoid arthritis	<a href="https://k4.ers.net.org/prod/v2/Front/Program/Session?e=379&amp;session=15939">https://k4.ers.net.org/prod/v2/Front/Program/Session?e=379&amp;session=15939</a>	Yes
13:45-15:15	Genetics in paediatric respiratory diseases	To present the main process and challenges of genetic data interpretation; to list the main genetic diagnostic tools and their limitations; to provide the audience with key tips to read a genetic report. to discuss importance of genotyping for three model monogenic diseases that can affect newborns or occur later in life (cystic fibrosis, surfactant disorders and primary ciliary dyskinesia): to illustrate the phenotype-genotype correlation diversity and gene/mutation(s) distinct consequences at the cell level; to explain the consequences of molecular diagnosis on vital prognosis at birth, follow-up, lung cancer risk later in life and genetic counselling; to explain how genotypes connect with current personalised treatments and their development.	Mini symposium	Includes a patient perspective	Cystic fibrosis / Primary ciliary dyskinesia (PCD)	<a href="https://k4.ers.net.org/prod/v2/Front/Program/Session?e=379&amp;session=15946">https://k4.ers.net.org/prod/v2/Front/Program/Session?e=379&amp;session=15946</a>	Yes
15:30-17:00	Next generation evidence-based decision-making in respiratory medicine	To explore the contribution of data from real-life research studies to decision-making processes including guidelines development; to emphasize the complementarity of real-life research and randomized controlled trials for the assessment of interventions; to discuss the yield of m-Health tools and the contribution and challenges of registries.	Mini symposium		ILD	<a href="https://k4.ers.net.org/prod/v2/Front/Program/Session?e=379&amp;session=16187">https://k4.ers.net.org/prod/v2/Front/Program/Session?e=379&amp;session=16187</a>	Yes
15:30-17:00	Treatment of early stage, technically	To review different international guidelines on treatment of mesothelioma; to present inconsistencies in the current set of	Symposium		Mesothelioma	<a href="https://k4.ers.net.org/prod/v2/Front/Program/Session?e=379&amp;session=16187">https://k4.ers.net.org/prod/v2/Front/Program/Session?e=379&amp;session=16187</a>	Yes

## ERS International Congress 2023 Rare Disease Patient Track

resectable mesothelioma	guidelines; to help delegates understand the use of these guidelines in optimal patient care.				<a href="https://k4.ersnet.org/program/Session?e=379&amp;session=16133">am/Session?e=379&amp;session=16133</a>
-------------------------	---	--	--	--	--

Wednesday 13 September							
Time CEST	Session title	Summary	Session type	Patient role	Disease area	Link	Live streamed?
9:45-12:45	How to build a successful, sustainable, international research network?	This session, led by ERS Clinical Research Collaborations (CRC), and EU projects, draws upon the experience of ERS membership and involvement of ERS and European Lung Foundation (ELF) in consortia. This session aims to explore the journey of building remarkable international research networks through key principles, effective strategies, and best practices, fostering cutting edge research with worldwide impact.	Wednesday special session	Includes a patient perspective	Primary ciliary dyskinesia (PCD)/ Childhood bronchiectasises	<a href="https://k4.ersnet.org/program/Session?e=379&amp;session=16304">https://k4.ersnet.org/program/Session?e=379&amp;session=16304</a>	Yes
10:00-11:20	Excellence in rare diseases care and research: the ERN-Lung initiative – the ERN-Lung go East	To present the ERN-LUNG Network and highlight some of its assets achieved during the past years through funding and support by the European Commission and the ERS; to learn from participants about their expectations and needs to better tailor initiative offerings and to offer a better support; to present the following take home messages: 1) There is always someone who knows more about this rare disease than myself; 2) ERN-LUNG is the place where to find and get in contact with this Expert across all of Europe.	Wednesday special session	Includes a patient perspective	Rare lung disease	<a href="https://k4.ersnet.org/program/Session?e=379&amp;session=16684">https://k4.ersnet.org/program/Session?e=379&amp;session=16684</a>	Yes